54887-20-6

Basic information

• Product Name: 1-Bromo-3-butylbenzene
• Synonyms: 1-Bromo-3-butylbenzene;3-Bromo-n-butylbenzene
• CAS NO: 54887-20-6
• Molecular Formula: C₁₀H₁₃Br
• Molecular Weight: 213.11422
• Mol File: 54887-20-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-Bromo-3-butylbenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-3-butylbenzene(54887-20-6)
• EPA Substance Registry System: 1-Bromo-3-butylbenzene(54887-20-6)

Safety Data

• Hazardous Substances Data: 54887-20-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-Bromo-3-butylbenzene is utilized as an intermediate in organic synthesis, serving as a key component in the creation of various organic compounds. Its unique structure allows for further chemical reactions that can lead to a wide array of products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 1-Bromo-3-butylbenzene is used as a building block for the synthesis of different types of pharmaceuticals. Its role in the production process is crucial for creating the desired medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Production:
Similarly, in the agrochemical sector, 1-Bromo-3-butylbenzene is employed in the synthesis of various agrochemicals. Its application in this industry aids in the development of products that can enhance crop protection and contribute to more efficient agricultural practices.
Given the compound's reactivity and structural features, 1-Bromo-3-butylbenzene is a versatile intermediate that finds applications across multiple industries, primarily in the synthesis of complex organic molecules for various end uses.

Upstream product

• 161173-98-4 1-bromo-3-(but-3-en-1-yl)benzene 
• 823-78-9 meta-bromobenzyl bromide 
• 927-77-5 n-propylmagnesium bromide 
• 519051-02-6 C₁₀H₁₃BrN₂ 
• 104-13-2 4-Butylaniline 
• 106-94-5 propyl bromide 
• 64-17-5 ethanol 
• 104605-80-3 1-bromo-3-but-1-enyl-benzene 
• 104-51-8 1-butylbenzene 
• 51605-98-2 2-bromo-4-butylaniline 

Downstream Products

• 218153-01-6 4-(3-bromophenyl)butan-1-ol 
• 1426408-95-8 5-(3-butylphenyl)-1-phenyl-1H-pyrazol-3-ylamine 
• 1426408-94-7 2-(3-butylphenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 54887-22-8 3-Butyl-benzoic acid 2-diethylamino-ethyl ester 
• 54887-21-7 m-butylbenzoyl chloride 
• 188753-18-6 1-(5-Butyl-2,4-dinitro-phenyl)-pyrrolidine 
• 1026394-25-1 N-(5-Acetylamino-4-butyl-2-pyrrolidin-1-yl-phenyl)-acetamide 
• 188753-25-5 1-(5-Butyl-2-nitro-phenyl)-pyrrolidine 
• 713517-83-0 5-(3-butyl-phenyl)-1-(4-methoxy-benzyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one 

Relevant articles and documents

MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules,

PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a pyrazole compound of the following general Formula [1b] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use wherein each symbol is the same as defined in the description

AMINO-5-[4-(DIFLUOROMETHOXY)-PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE

The present invention provides a 2-amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists

Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ET A/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo[e] [1,4]diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.

Bromination of alkylbenzenes in organic solvents. Substrate and position selectivity and effects of substituents

The relative reactivity and the orientation of the entering group in the reaction of bromine with alkylbenzenes (C1-C4 alkyl groups, the last two with normal and iso structures) in organic solvents (acetic acid, acetic anhydride, nitromethane) under polythermal conditions (25-75 deg C) are determined mainly by the steric effects of the substituents.Nathan-Baker position and substrate effects are observed.Correlations close to linear are observed between the orientation (in the form of log 2P/O, where P and O are the relative amounts of the isomers in their reaction mixture) and the purely steric constants of the alkyl groups Es0.The substrate selectivity depends nonlinearly and inversely on Es0.The sensitivity of the orientation to change in the steric characteristics of the substituents shows an extremal dependence on the temperature with a maximum at about 50 deg C.